February 10th, 2023
•Here, we describe a protocol in which an acute lymphoblastic leukemia patient-derived xenograft model is used as a strategy to assess and monitor CD19-targeted chimeric antigen receptor T cell-associated toxicities.
Related Videos
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies (Video) | JoVE
Preparation of Primary Acute Lymphoblastic Leukemia Cells in Different Cell Cycle Phases by Centrifugal Elutriation (Video) | JoVE
Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up (Video) | JoVE
Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells (Video) | JoVE
Assessment of the Metabolic Profile of Primary Leukemia Cells (Video) | JoVE
In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function (Video) | JoVE
Patient-derived Heterogeneous Xenograft Model of Pancreatic Cancer Using Zebrafish Larvae as Hosts for Comparative Drug Assessment (Video) | JoVE
A Melanoma Patient-Derived Xenograft Model (Video) | JoVE
Establishment of Gastric Cancer Patient-derived Xenograft Models and Primary Cell Lines (Video) | JoVE
Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy (Video) | JoVE
ABOUT JoVE
Copyright © 2024 MyJoVE Corporation. All rights reserved